# QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors

> **NCT00563680** · PHASE2 · COMPLETED · sponsor: **NantCell, Inc.** · enrollment: 38 (actual)

## Conditions studied

- Askin's Tumors
- Desmoplastic Small Round Cell Tumors
- Estraosseous Ewing's Tumor
- Ewing's Family Tumor
- Ewing's Sarcoma
- Primitive Neuroectodermal Tumors (PNETs)
- Sarcoma

## Interventions

- **DRUG:** AMG 479

## Key facts

- **NCT ID:** NCT00563680
- **Lead sponsor:** NantCell, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2009-08
- **Final completion:** 2012-08
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2016-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00563680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00563680, "QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00563680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*